Company Description
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.
The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.
The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions.
It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne.
The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016.
STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
| Country | United States |
| Founded | 1989 |
| IPO Date | Oct 28, 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 99 |
| CEO | Dolev Rafaeli |
Contact Details
Address: 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 United States | |
| Phone | 215 619 3200 |
| Website | strataskinsciences.com |
Stock Details
| Ticker Symbol | SSKN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001051514 |
| CUSIP Number | 86272A206 |
| ISIN Number | US86272A2069 |
| Employer ID | 13-3986004 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dolev Rafaeli Ph.D. | President, Chief Executive Officer and Vice-Chairman |
| Shmuel Gov | Chief Operating Officer |
| John Gillings | Vice President of Finance |
| Jay Sturm | General Counsel and Corporate Secretary |
| Michael R. Stewart | Independent Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Sep 26, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 26, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |